Medical AI Alliance
← Company Index
Biotech & Drug DiscoveryKOSDAQ 2846204 trials

KAINOS MEDICINE, INC.

Official website

License-out focused drug developer behind the Parkinson's disease candidate KM-819 and the HIV therapy KM-023.

As of 2026-10-08, KAINOS MEDICINE, INC. has 13 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).

Price

Change

Market cap

Business overview

Source: DART corporate disclosure

Founded in 2017 and listed on KOSDAQ in 2018, the company develops new drug candidates on a license-out business model. Its pipeline includes the Parkinson's disease drug KM-819, a multiple system atrophy (MSA) candidate, the HIV therapy KM-023, and the anticancer candidates IRAK4 and FAF1-novel delivery. KM-819 received FDA Phase 2 IND approval in the US, and its MSA indication received Korea Phase 2 IND approval from the MFDS in October 2025; KM-023, licensed to Chinese partner Jiangsu Aidea Pharm., saw ACC007 gain Chinese NDA approval in 2021 and ACC008 in 2023.

Products & technology

  • ACC007 (Ainuovirine)HIV therapy
  • ACC008 (Ainuomiti)HIV therapy, single-tablet combination (ACC007+TDF+3TC)

Clinical trials

data.go.kr

4 MFDS clinical trial authorisations · 2015–2025 (Phase 2 2 · Phase 1 2)

  • Phase 2KM-819정2025-10-20

    2 trial sites

  • Phase 2KM-819정2021-10-22

    2 trial sites

  • Phase 1KM-819정2016-10-21

    1 trial site

  • Phase 1KM-819정2015-12-29

    1 trial site

Global clinical trials

ClinicalTrials.gov · sponsor-matched

R&D and key agreements

Source: DART corporate disclosure

KM-819 · 파킨슨병 · 미국 FDA 임상2상 IND 승인, Part1a/1b 완료 · Developed via US subsidiary FAScinate; Phase 2 IND approved by FDA, Part 1a/1b completed, addressing FDA comments to proceed to Part 2

KM-819 (MSA 적응증) · 다계통위축증(MSA) · 한국 임상2상 IND 승인(2025.10) · Same compound as KM-819 for MSA; Korea Phase 2 IND approved by MFDS in Oct 2025; US clinical site expansion under discussion

KM-023 · 에이즈(HIV) · 기술이전 완료, 상업화 단계(파트너사) · Licensed to Jiangsu Aidea Pharm. for China (incl. Taiwan, Hong Kong) in 2014; global rights (ex-Korea) licensed in April 2023

IRAK4 · 혈액암(백혈병, 림프종) · 공동연구개발 및 기술이전 완료, 파트너사 후속연구 중단 · Co-development and license agreement with US-based Emmaus in 2021; Emmaus holds US/EU/UK commercial rights but follow-up research is paused due to its financial situation; company retains rights elsewhere

FAF1-novel delivery · 항암(적응증 미정) · 초기 후보물질 창출 연구단계 · Early hit-to-lead research completed; platform development and preclinical candidate selection ongoing

Key disclosures

KRX KIND via OpenDART
Show 23 more events

Publications

PubMed · affiliation-matched
Show 3 more publications

Patents

KIPRIS · applicant-matched
Show 55 more patents

AI reads

MAA server logs · IP-verified
31
Times AI engines pulled KAINOS MEDICINE, INC.'s records

Pulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.

0
Fetched fresh mid-answer

Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.

31
Index crawls

Collected as raw material for future answers.

0
Direct AI-tool queries (MCP)

Queries from users who connected this index to their own AI.

5
live 0
Last 7 days
26
live 0
Last 30 days
31
live 0
All time
  • OpenAIOAI-SearchBot27
  • AnthropicClaudeBot2
  • GoogleGoogleOther1
  • PerplexityPerplexityBot1

Measured since Aug 27, 2026 · 4 AI engines · last read Oct 7, 2026

User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.

Connect this index to your AI tool →

Connect this company index directly to your AI

Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for KAINOS MEDICINE, INC. and every listed Korean medical, bio and AI company.

How to connect (MCP)
Not yet compiled: business overview · regulatory approvals. Send us materials and we will add them

Companies in the same categoryBiotech & Drug Discovery

AHNLAB,INC.100

KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.

Inventage Lab Inc.100

Drug delivery system company behind the long-acting injectable platform IVL-DrugFluidic and the LNP delivery platform IVL-GeneFluidic.

ORGANOIDSCIENCES LTD.100

Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.

Eone Diagnomics Genome Center Co., Ltd.85

EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.

SK Chemicals Co., Ltd.85

A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.

CG Invites Co., Ltd.85

Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.

Y-Biologics, Inc85

KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.

GC Corp.85

A holding company overseeing 54 affiliates including its main biopharmaceutical subsidiary GC, with no direct product manufacturing of its own.

Prestige BioPharma Limited85

Founded in 2015 and listed on KOSPI in 2021, Prestige BioPharma develops antibody biosimilars and novel antibody drugs including Tuznue.

GENEMATRIX INC.85

KOSDAQ-listed biotech company developing molecular diagnostics with proprietary C-Tag technology and the NeoPlex product line.

SillaJen, Inc.85

SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.

SK Bioscience Co.,Ltd84

A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.

Sources and updates

Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.

Company basics
Korea Exchange · DART
Business content
Compiled from disclosure filings
Approvals & clinical trials
Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
Key disclosures
KRX KIND via OpenDART exchange filings — updated daily
Global clinical trials
ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
Financials
DART corporate disclosure filings — annual
Publications
PubMed (US National Library of Medicine) — affiliation-matched, updated daily
Patents
KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
AI reads
Our server logs, IP-verified every 6 hours
AI visibility
Measured 2026-10-01

This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.

Request a correction or addition